Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial
- 24 May 2010
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 81 (10), 1135-1140
- https://doi.org/10.1136/jnnp.2009.200642
Abstract
Background Many patients with amyotrophic lateral sclerosis (ALS) experience cramps during the course of the disease but so far, none of the medications used has been of proven benefit. The objective was to determine the effect of orally administered tetrahydrocannabinol (THC) on cramps in ALS patients. Methods The authors conducted a randomised, double-blind, placebo-controlled crossover trial in 27 ALS patients suffering from moderate to severe (visual analogue scale (VAS); VAS≥4) daily cramps. There were 7 women and 20 men with a mean age of 57 years and a mean functional ALS score (ALSFRS-R) of 38.4. Patients were randomly assigned to receive 5 mg THC twice daily followed by placebo or vice versa. Each treatment period lasted for 2 weeks and was preceded by a 2-week drug-free observation period (run-in, wash-out period respectively). The primary outcome measure was change in cramp intensity as assessed by a VAS. Secondary outcome measures included the number of cramps per day, number of cramps during daytime and bedtime, intensity of fasciculations (VAS) as well as validated measures of quality of life (ALSAQ-40), quality of sleep (SDQ), appetite (FAACT) and depression (HADS). Results Complete data were available from 22 patients. THC was well tolerated. There was no evidence for a treatment effect on cramp intensity, number of cramps, fasciculation intensity or any of the other secondary outcome measures. Conclusions This interventional study with orally administered THC 5 mg twice daily did not demonstrate subjective improvement of cramp intensity in ALS patients.This publication has 33 references indexed in Scilit:
- Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2009
- Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron diseaseAmyotrophic Lateral Sclerosis, 2009
- Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicityEuropean Journal of Neuroscience, 2008
- Endocannabinoids mediate muscarine‐induced synaptic depression at the vertebrate neuromuscular junctionEuropean Journal of Neuroscience, 2007
- The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJournal of Neurochemistry, 2007
- Survey of cannabis use in patients with amyotrophic lateral sclerosisAmerican Journal of Hospice and Palliative Medicine®, 2004
- Long-term safety of riluzole in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2002
- Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40Amyotrophic Lateral Sclerosis, 2000
- Muscle cramp as the result of impaired gaba function—an electrophysiological and pharmacological observationMuscle & Nerve, 1993
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983